Opinion statement
Transplantation of bone marrow or peripheral blood stem cells is increasingly being used to treat a variety of oncologic disorders. These procedures are associated with a large spectrum of neurologic complications that significantly contribute to patient morbidity and mortality. These complications may arise at any time during and after the transplantation process and are particularly common in patients requiring chronic immunosuppression. The most frequent complications are infections and cerebrovascular or metabolic events, and toxicity from radiation or chemotherapy. Because of the unique circumstances and treatments involved in each step of the transplantation process, there is a higher incidence of some neurologic complications during discrete time periods, and an awareness of the temporal relationship of the neurologic disorder to the transplantation process facilitates diagnosis. With the exception of post-transplant lymphoproliferative disorder, in which reduced immunosuppression may be an effective therapeutic strategy, therapies are often the same as in the nontransplant patient. Complications of therapy can arise because of the presence of multiple comorbidities and medication interactions. Anticipation of common opportunistic infections and appropriate use of prophylactic medications can significantly reduce the incidence of infectious complications.
Similar content being viewed by others
References and Recommended Reading
Bleggi-Torres LF, de Medeiros BC, Werner B, et al.: Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 2000, 25:301–307.
Snider S, Bashir R, Bierman P: Neurologic complications after high-dose chemotherapy and autologous bone marrow transplantation for Hodgkin’s disease. Neurology 1994, 44:681–684.
de Brabander C, Cornelissen J, Smitt PA, et al.: Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry 2000, 68:36–40.
Graus F, Saiz A, Sierra J, et al.: Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study. Neurology 1996, 46:1004–1009.
Sostak P, Padovan CS, Yousry TA, et al.: Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003, 60:842–848.
Faraci M, Lanino E, Dini G, et al.: Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology 2002, 59:1895–1904.
Uckan D, Cetin M, Yigitkanli I, et al.: Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant 2005, 35:71–76.
Burt RK, Fassas A, Snowden J, et al.: Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001, 28:1–12.
Openshaw H, Stuve O, Antel JP, et al.: Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000, 54:2147–2150.
De La Camara R, Tomas JF, Figuera A, et al.: High dose busulfan and seizures. Bone Marrow Transplant 1991, 7:363–364.
Pelgrims J, De Vos F, Van den B J, et al.: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291–294.
Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S: Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ‘what is the best recipe?’. Bone Marrow Transplant 2005, 36:565–574.
Lee HJ, Oran B, Saliba RM, et al.: Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 2006, 38:299–303.
Batchelor TT, Taylor LP, Thaler HT, et al.: Steroid myopathy in cancer patients. Neurology 1997, 48:1234–1238.
Freise CE, Rowley H, Lake J, et al.: Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. Transplant Proc 1991, 23:3173–3174.
Erer B, Polchi P, Lucarelli G, et al.: CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant 1996, 18:157–162.
Gaggero R, Haupt R, Paola FM, et al.: Intractable epilepsy secondary to cyclosporine toxicity in children undergoing allogeneic hematopoietic bone marrow transplantation. J Child Neurol 2006, 21:861–866.
Hinchey J, Chaves C, Appignani B, et al.: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494–500.
Pranzatelli MR, Mott SH, Pavlakis SG, et al.: Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994, 10:131–140.
Balmaceda CM, Walker RW, Castro-Malaspina H, Dalmau J: Reversal of amphotericin-B-related encephalopathy. Neurology 1994, 44:1183–1184.
Krouwer HG, Wijdicks EF: Neurologic complications of bone marrow transplantation. Neurol Clin 2003, 21:319–352.
Cree BC, Bernardini GL, Hays AP, Lowe G: A fatal case of coxsackievirus B4 meningoencephalitis. Arch Neurol 2003, 60:107–112.
Wainwright MS, Martin PL, Morse RP, et al.: Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol 2001, 50:612–619.
Spitzer TR: Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:893–898.
Oyama Y, Cohen B, Traynor A, et al.: Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002, 29:81–85.
Hoyt R, Szer J, Grigg A: Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone Marrow Transplant 2000, 25:1285–1287.
Vos PE, de Boer WA, Wurzer JA, van Gijn J: Subdural hematoma after lumbar puncture: two case reports and review of the literature. Clin Neurol Neurosurg 1991, 93:127–132.
Pickhardt PJ, Siegel MJ: Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999, 213:73–78.
Miller WT Jr, Siegel SG, Montone KT: Posttransplantation lymphoproliferative disorder: changing manifestations of disease in a renal transplant population. Crit Rev Diagn Imaging 1997, 38:569–585.
Castellano-Sanchez AA, Li S, Qian J, et al.: Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004, 121:246–253.
Nozzoli C, Bartolozzi B, Guidi S, et al.: Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2006, 47:167–169.
Sundin M, Le Blanc K, Ringden O, et al.: The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006, 91:1059–1067.
Rosenfeld MR, Pruitt A: Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol 2006, 33:352–361.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mathew, R.M., Rosenfeld, M.R. Neurologic complications of bone marrow and stem-cell transplantation in patients with cancer. Curr Treat Options Neurol 9, 308–314 (2007). https://doi.org/10.1007/s11940-007-0016-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-007-0016-3